PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28778815-2 2017 This study investigated whether 14 days of the selective Cox-2 inhibitor etoricoxib (60 mg/day) would modify self-report of pain intensity and quality, and physical measures of hyperalgesia and function in individuals with knee OA. Etoricoxib 73-83 mitochondrially encoded cytochrome c oxidase II Homo sapiens 57-62 35453005-7 2022 Young patients, patients dealing with acute pain, or with active and/or chronic symptomatic gastritis, selective COX-2 inhibitors (celecoxib or etoricoxib) may be a better option (level of evidence 2). Etoricoxib 144-154 mitochondrially encoded cytochrome c oxidase II Homo sapiens 113-118 32606658-1 2020 Aim: Etoricoxib is a selective inhibitor of COX-2 enzyme. Etoricoxib 5-15 mitochondrially encoded cytochrome c oxidase II Homo sapiens 44-49 30636337-10 2019 Since its introduction in 2003, the use of etoricoxib, a newer selective COX-2 inhibitor, increased in all countries except Denmark, with highest sales in Finland (6.7 DDD/1000 inhabitants/day in 2016). Etoricoxib 43-53 mitochondrially encoded cytochrome c oxidase II Homo sapiens 73-78 35585779-6 2022 Rofecoxib (Vioxx) was withdrawn from the market for this reason, but the equally COX-2 selective etoricoxib has replaced it in Europe but not in the US. Etoricoxib 97-107 mitochondrially encoded cytochrome c oxidase II Homo sapiens 81-86 32989835-2 2020 The COX-2 inhibitor etoricoxib, in particular, was studied. Etoricoxib 20-30 mitochondrially encoded cytochrome c oxidase II Homo sapiens 4-9 30983880-0 2019 Effects of the Highly COX-2-Selective Analgesic NSAID Etoricoxib on Human Periodontal Ligament Fibroblasts during Compressive Orthodontic Mechanical Strain. Etoricoxib 54-64 mitochondrially encoded cytochrome c oxidase II Homo sapiens 22-27 30983880-2 2019 The highly COX-2-selective NSAID etoricoxib has a favorable systemic side effect profile and high analgesic efficacy, particularly for orthodontic pain. Etoricoxib 33-43 mitochondrially encoded cytochrome c oxidase II Homo sapiens 11-16 30983880-10 2019 Clinically dosed etoricoxib, that is, a highly selective COX-2 inhibition, did not have substantial effects on hPDL fibroblast-mediated periodontal inflammation, extracellular matrix remodeling, RANK-L/OPG expression, and osteoclastogenesis during simulated orthodontic compressive strain. Etoricoxib 17-27 mitochondrially encoded cytochrome c oxidase II Homo sapiens 57-62 27779319-5 2016 Their IC50 values against the COX-2 enzyme were 0.67 and 0.85 microM, respectively, which is more potent than etoricoxib. Etoricoxib 110-120 mitochondrially encoded cytochrome c oxidase II Homo sapiens 30-35 28057325-0 2017 Design, synthesis and biological screening of some novel celecoxib and etoricoxib analogs with promising COX-2 selectivity, anti-inflammatory activity and gastric safety profile. Etoricoxib 71-81 mitochondrially encoded cytochrome c oxidase II Homo sapiens 105-110 28210513-0 2017 Seizure following the Use of the COX-2 Inhibitor Etoricoxib. Etoricoxib 49-59 mitochondrially encoded cytochrome c oxidase II Homo sapiens 33-38 28210513-4 2017 Neuroimaging and blood samples studies did not evidence alterations, but a careful pharmacological history revealed that the patient had taken the COX-2 inhibitor etoricoxib to treat lumbago few days before the onset of clinical symptoms. Etoricoxib 163-173 mitochondrially encoded cytochrome c oxidase II Homo sapiens 147-152 28676124-10 2017 Another finding was the concomitant use of COX-2 inhibitors (Etoricoxib or Celecoxib) and PPIs. Etoricoxib 61-71 mitochondrially encoded cytochrome c oxidase II Homo sapiens 43-48 28884717-7 2017 A drug of choice in case of intensive pain and marked nociceptive component are highly effective and safe nonsteroidal anti-inflammatory drugs, in particular etoricoxib (Arcoxia), a selective COX-2 inhibitor. Etoricoxib 158-168 mitochondrially encoded cytochrome c oxidase II Homo sapiens 192-197 28884717-7 2017 A drug of choice in case of intensive pain and marked nociceptive component are highly effective and safe nonsteroidal anti-inflammatory drugs, in particular etoricoxib (Arcoxia), a selective COX-2 inhibitor. Etoricoxib 170-177 mitochondrially encoded cytochrome c oxidase II Homo sapiens 192-197 27576781-1 2016 WHAT IS KNOWN AND OBJECTIVE: Etoricoxib is a non-steroidal anti-inflammatory drug (NSAID) that inhibits the inducible cyclooxygenase (COX-2) with a good safety profile. Etoricoxib 29-39 mitochondrially encoded cytochrome c oxidase II Homo sapiens 134-139 23964558-2 2013 OBJECTIVE: To evaluate tolerability to etoricoxib, a second-generation COX-2 inhibitor with high in vitro selectivity for COX-2 in patients with AERD. Etoricoxib 39-49 mitochondrially encoded cytochrome c oxidase II Homo sapiens 71-76 27007068-0 2016 Evidence for a central mode of action for etoricoxib (COX-2 inhibitor) in patients with painful knee osteoarthritis. Etoricoxib 42-52 mitochondrially encoded cytochrome c oxidase II Homo sapiens 54-59 27007068-1 2016 The COX-2 inhibitor etoricoxib modulates the peripheral and central nociceptive mechanisms in animals. Etoricoxib 20-30 mitochondrially encoded cytochrome c oxidase II Homo sapiens 4-9 26904451-2 2015 Etoricoxib is a second-generation cox-2 inhibitor and as its use increases so do the reports of side effects. Etoricoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 34-39 25229174-1 2014 Etoricoxib is a newer cyclooxygenase (COX)-2 inhibitor anti-inflammatory drug with a favorable safety profile. Etoricoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 22-44 24469906-7 2014 The local COX-2 inhibition by etoricoxib was most pronounced for PGD2. Etoricoxib 30-40 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 24469906-9 2014 CONCLUSIONS: Doses of 50 mg lumiracoxib and 90 mg etoricoxib produced similar maximum inhibition of systemic COX-2 function whereas 50 mg lumiracoxib was ineffective in producing local COX-2 inhibition. Etoricoxib 50-60 mitochondrially encoded cytochrome c oxidase II Homo sapiens 109-114 24383977-2 2013 Etoricoxib, a cox-2 inhibitor NSAID, has been shown to be a safe alternative in these patients. Etoricoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 14-19 24352312-1 2013 AIMS: Etoricoxib is a second-generation selective COX-2 inhibitor. Etoricoxib 6-16 mitochondrially encoded cytochrome c oxidase II Homo sapiens 50-55 27502582-0 2016 Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial. Etoricoxib 27-37 mitochondrially encoded cytochrome c oxidase II Homo sapiens 41-46 27502582-2 2016 Etoricoxib is a COX-2 selective NSAID that has demonstrated efficacy in the treatment of RA at a dose of 90 mg. Etoricoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 16-21 26838881-2 2016 Etoricoxib (COX-2 inhibitor), a highly hydrophobic drug was chosen as a model drug for the study. Etoricoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 12-17 25029569-1 2014 AIM: The present meta-analysis attempted to assess whether an unfavourable cardiovascular risk profile could be identified in the case of two COX2 selective inhibitors (COXIBs), namely celecoxib and etoricoxib. Etoricoxib 199-209 mitochondrially encoded cytochrome c oxidase II Homo sapiens 142-146 24461582-3 2014 OBJECTIVE: To determine the effects of the selective COX-2 inhibitor, etoricoxib, on allergen-induced bronchoconstriction in asthmatic subjects. Etoricoxib 70-80 mitochondrially encoded cytochrome c oxidase II Homo sapiens 53-58 23964558-2 2013 OBJECTIVE: To evaluate tolerability to etoricoxib, a second-generation COX-2 inhibitor with high in vitro selectivity for COX-2 in patients with AERD. Etoricoxib 39-49 mitochondrially encoded cytochrome c oxidase II Homo sapiens 122-127 23964558-7 2013 CONCLUSIONS: The highly selective COX-2 inhibitor etoricoxib was tolerated in most but not all patients tested. Etoricoxib 50-60 mitochondrially encoded cytochrome c oxidase II Homo sapiens 34-39 23265037-1 2012 BACKGROUND: Etoricoxib, a selective Cox-2 inhibitor has been found to be effective in the management of acute pain. Etoricoxib 12-22 mitochondrially encoded cytochrome c oxidase II Homo sapiens 36-41 21848948-3 2012 Etoricoxib, a Cox-2 inhibitor with a 22-hour half-life, has been shown effective in preventing fasting headache when taken just prior to the 25-hour Yom Kippur fast. Etoricoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 14-19 22582102-11 2012 CONCLUSION: The current study estimated the efficacy of acetaminophen, nsNSAIDs, and COX-2 selective NSAIDs in OA and found that etoricoxib 30 mg is likely to result in the greatest improvements in pain and physical function. Etoricoxib 129-139 mitochondrially encoded cytochrome c oxidase II Homo sapiens 85-90 21539467-9 2011 In a control experiment, patients (n = 6) treated with the selective COX-2 inhibitor etoricoxib (90 mg/day) for 8 weeks showed no changes in the number of pMPs, eMPs, and EPCs and in FMD. Etoricoxib 85-95 mitochondrially encoded cytochrome c oxidase II Homo sapiens 69-74 21905970-1 2011 OBJECTIVE: To further assess the clinically active dose range of etoricoxib, a COX-2 selective inhibitor, in rheumatoid arthritis (RA). Etoricoxib 65-75 mitochondrially encoded cytochrome c oxidase II Homo sapiens 79-84 21373319-9 2010 Non-steroidal analgesics and other COX-2 inhibitors (rofecoxib and celecoxib) have been known to precipitate renal failure and hyperkalemia specially in patients at risk for the same; although not unexpected, this may be the first reported case of life-threatening hyperkalemia precipitated by etoricoxib in a previously stable patient having increased risk of renal failure and hyperkalemia. Etoricoxib 294-304 mitochondrially encoded cytochrome c oxidase II Homo sapiens 35-40 20678677-3 2010 OBJECTIVE: The aim of this study was to assess the annual incidence of and identify the risk factors for clinical upper GI events in chronic COX-2 inhibitor (celecoxib and etoricoxib) users. Etoricoxib 172-182 mitochondrially encoded cytochrome c oxidase II Homo sapiens 141-146 20678677-4 2010 METHODS: A prospective, hospital-based, observational cohort study was conducted in patients taking COX-2 inhibitors (celecoxib or etoricoxib) without comorbidity. Etoricoxib 131-141 mitochondrially encoded cytochrome c oxidase II Homo sapiens 100-105 20399943-11 2010 GA with premedication: The cyclooxygenase (COX)-2 inhibitor etoricoxib; the nonselective COX inhibitors lornoxicam, diclofenac and ketorolac IM; and the opioid nalbuphine improved postoperative pain. Etoricoxib 60-70 mitochondrially encoded cytochrome c oxidase II Homo sapiens 27-49 20504378-1 2010 BACKGROUND AND OBJECTIVE: Our objective was to report on the design and essentials of the Etoricoxib protocol- Preemptive and Postoperative Analgesia (EPPA) Trial, investigating whether preemptive analgesia with cox-2 inhibitors is more efficacious than placebo in patients who receive either laparotomy or thoracotomy. Etoricoxib 90-100 mitochondrially encoded cytochrome c oxidase II Homo sapiens 212-217 20363696-2 2010 Etoricoxib is a new non-steroidal anti-inflammatory drug (NSAID) with selective cox-2 inhibitory activity, selective inhibition of cox-2 provides anti-inflammatory and analgesic activity it is commonly used for osteo-arthritis, rheumatoid arthritis, primary dysmenorrhoea, post operative dental pain and acute gout. Etoricoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 80-85 20363696-2 2010 Etoricoxib is a new non-steroidal anti-inflammatory drug (NSAID) with selective cox-2 inhibitory activity, selective inhibition of cox-2 provides anti-inflammatory and analgesic activity it is commonly used for osteo-arthritis, rheumatoid arthritis, primary dysmenorrhoea, post operative dental pain and acute gout. Etoricoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 131-136 19634927-1 2009 Etoricoxib is a selective cyclo-oxygenase (COX)-2 inhibitor, approved in Europe for the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis. Etoricoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 26-49 19589894-0 2009 Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and placebo. Etoricoxib 140-150 mitochondrially encoded cytochrome c oxidase II Homo sapiens 18-23 23100954-5 2008 We found a short course of Cox-2 (etoricoxib) inhibitor to be an extremely useful adjunct. Etoricoxib 34-44 mitochondrially encoded cytochrome c oxidase II Homo sapiens 27-32 19470170-13 2009 The cox-2 inhibitor Etoricoxib was found to negate or increase the action of two other drugs (Leflunomide and Dexamethasone). Etoricoxib 20-30 mitochondrially encoded cytochrome c oxidase II Homo sapiens 4-9 16598848-0 2006 Different COX-independent effects of the COX-2 inhibitors etoricoxib and lumiracoxib. Etoricoxib 58-68 mitochondrially encoded cytochrome c oxidase II Homo sapiens 41-46 19209280-7 2008 We will describe possible strategies to reduce the side effects of etoricoxib by using biochemical markers of COX inhibition, such as whole blood COX-2 and the assessment of prostacyclin biosynthesis in vivo. Etoricoxib 67-77 mitochondrially encoded cytochrome c oxidase II Homo sapiens 146-151 18434566-0 2008 Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects. Etoricoxib 35-45 mitochondrially encoded cytochrome c oxidase II Homo sapiens 76-81 18182814-1 2008 Etoricoxib is a new, highly selective cyclooxygenase (COX) 2 inhibitor, reported to have an increased cutaneous and systemic safety profile compared to the previous COX-2 inhibitors, including celecoxib, rofecoxib and valdecoxib. Etoricoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 38-60 18182814-1 2008 Etoricoxib is a new, highly selective cyclooxygenase (COX) 2 inhibitor, reported to have an increased cutaneous and systemic safety profile compared to the previous COX-2 inhibitors, including celecoxib, rofecoxib and valdecoxib. Etoricoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 165-170 17953635-4 2007 This study aimed to detect tolerability of etoricoxib, a selective COX-2-inhibiting drug, in patients with chronic urticaria with a history of NSAID intolerance. Etoricoxib 43-53 mitochondrially encoded cytochrome c oxidase II Homo sapiens 67-72 17953635-7 2007 The study suggests that etoricoxib, with its favourable COX-1/COX-2 ratio, is well tolerated by patients with chronic urticaria exacerbated by NSAID intolerance. Etoricoxib 24-34 mitochondrially encoded cytochrome c oxidase II Homo sapiens 62-67 17691997-2 2007 Etoricoxib and lumiracoxib are regarded as second generation coxibs because of their higher COX-2 selectivity. Etoricoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 92-97 18171381-0 2008 Primary stabbing headache can be responsive to etoricoxib, a selective COX-2 inhibitor. Etoricoxib 47-57 mitochondrially encoded cytochrome c oxidase II Homo sapiens 71-76 18564626-3 2008 Here we report the safety and tolerability of etoricoxib, a selective COX-2 inhibitor with fewer cardiovascular effects, in patients with adverse reactions to NSAIDs. Etoricoxib 46-56 mitochondrially encoded cytochrome c oxidase II Homo sapiens 70-75 17292766-9 2007 INTERPRETATION: There were significantly fewer upper gastrointestinal clinical events with the COX-2 selective inhibitor etoricoxib than with the traditional NSAID diclofenac due to a decrease in uncomplicated events, but not in the more serious complicated events. Etoricoxib 121-131 mitochondrially encoded cytochrome c oxidase II Homo sapiens 95-100 17265571-0 2006 Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib. Etoricoxib 104-114 mitochondrially encoded cytochrome c oxidase II Homo sapiens 78-83 17265571-1 2006 BACKGROUND: A pooled analysis of randomized clinical trials data was performed to compare the rate of thrombotic cardiovascular events (thrombotic events) in patients taking the COX-2 selective inhibitor (coxib) etoricoxib, a traditional NSAID, or placebo. Etoricoxib 212-222 mitochondrially encoded cytochrome c oxidase II Homo sapiens 178-183 16598848-1 2006 Etoricoxib and lumiracoxib are both highly selective COX-2 inhibitors. Etoricoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 53-58 16083531-5 2005 Highly selective COX-2 inhibitors including celecoxib, rofecoxib, valdecoxib, lumiracoxib, and etoricoxib were developed with the hope of significantly reducing the serious gastrointestinal toxicities associated with chronic high-dose NSAID use. Etoricoxib 95-105 mitochondrially encoded cytochrome c oxidase II Homo sapiens 17-22 16224508-1 2005 OBJECTIVE: To determine the risk of thromboembolic cardiovascular events associated with the use of etoricoxib, a COX-2 inhibitor. Etoricoxib 100-110 mitochondrially encoded cytochrome c oxidase II Homo sapiens 114-119 16224508-11 2005 However, the limited data that were available provide weak evidence of an increased cardiovascular risk with etoricoxib consistent with a class effect for COX-2 inhibitors. Etoricoxib 109-119 mitochondrially encoded cytochrome c oxidase II Homo sapiens 155-160 16922642-1 2005 Etoricoxib is a highly selective COX-2 inhibitor (coxib) approved in Europe for the treatment of osteoarthritis (OA), rheumatoid arthritis and acute gouty arthritis. Etoricoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 33-38 16922642-7 2005 Similarly to other selective COX-2 inhibitors, etoricoxib is contraindicated in patients with ischaemic heart disease or stroke and it should be used with caution in patients with risk factors for heart disease. Etoricoxib 47-57 mitochondrially encoded cytochrome c oxidase II Homo sapiens 29-34 16291600-1 2006 This 2-part, double-blind, placebo-controlled study was conducted to determine the safety and efficacy of etoricoxib, a COX-2 selective inhibitor, for the treatment of hemophilic arthropathy. Etoricoxib 106-116 mitochondrially encoded cytochrome c oxidase II Homo sapiens 120-125 16454836-0 2006 The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Etoricoxib 62-72 mitochondrially encoded cytochrome c oxidase II Homo sapiens 86-91 16454836-2 2006 Etoricoxib is a new antiinflammatory inhibitor that has high Cox-2 selectivity. Etoricoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 61-66 16321158-1 2005 BACKGROUND: The aim of this study was to evaluate the long-term efficacy and tolerability of etoricoxib, a COX-2 selective inhibitor, in osteoarthritis (OA) patients. Etoricoxib 93-103 mitochondrially encoded cytochrome c oxidase II Homo sapiens 107-112 15990304-4 2005 Additionally, FlexX and CoMFA results also suggested that etoricoxib, another selective COX-2 inhibitor, could inhibit p38 MAP kinase. Etoricoxib 58-68 mitochondrially encoded cytochrome c oxidase II Homo sapiens 88-93 15701208-2 2004 OBJECTIVE: To compare the rates of new use of gastroprotective agents and discontinuations due to dyspepsia with the COX-2 selective inhibitor etoricoxib compared with non-selective NSAIDs. Etoricoxib 143-153 mitochondrially encoded cytochrome c oxidase II Homo sapiens 117-122 15974563-2 2005 Etoricoxib, a COX-2 specific inhibitor, was developed to provide similar efficacy and less GI toxicity than non-selective NSAIDs. Etoricoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 14-19 16372792-1 2005 The study is a prospective randomized double blind clinical trial comparing the efficacy of nonselective NSAIDs (Aceclofenac) and highly selective COX-2 inhibitors (Etoricoxib) in post extraction pain control. Etoricoxib 165-175 mitochondrially encoded cytochrome c oxidase II Homo sapiens 147-152 15494548-5 2005 Valdecoxib potently inhibits recombinant COX-2, with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for rofecoxib, and 5 microM for etoricoxib. Etoricoxib 182-192 mitochondrially encoded cytochrome c oxidase II Homo sapiens 41-46 15494548-6 2005 Unique binding interactions of valdecoxib with COX-2 translate into a fast rate of inactivation of COX-2 (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for etoricoxib). Etoricoxib 170-180 mitochondrially encoded cytochrome c oxidase II Homo sapiens 47-52 15494548-6 2005 Unique binding interactions of valdecoxib with COX-2 translate into a fast rate of inactivation of COX-2 (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for etoricoxib). Etoricoxib 170-180 mitochondrially encoded cytochrome c oxidase II Homo sapiens 99-104 15494548-7 2005 The overall saturation binding affinity for COX-2 of valdecoxib is 2.6 nM (compared with 1.6 nM for celecoxib, 51 nM for rofecoxib, and 260 nM for etoricoxib), with a slow off-rate (t(1/2) approximately 98 min). Etoricoxib 147-157 mitochondrially encoded cytochrome c oxidase II Homo sapiens 44-49 15270001-1 2004 Etoricoxib (Arcoxia) is a novel non steroidal anti-inflammatory drug (NSAID) that selectively inhibits the inducible form of cyclo-oxygenase (COX), COX-2. Etoricoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 148-153 15117884-2 2004 Selective inhibitors of COX-2, such as celecoxib, etoricoxib, lumiracoxib, rofecoxib, and valdecoxib have been developed and the greatest recent growth in our knowledge in this area has been come from the clinical use of these compounds. Etoricoxib 50-60 mitochondrially encoded cytochrome c oxidase II Homo sapiens 24-29 15279595-1 2004 Valdecoxib, parecoxib, etoricoxib and lumiracoxib represent the second generation of selective COX-2 inhibitors. Etoricoxib 23-33 mitochondrially encoded cytochrome c oxidase II Homo sapiens 95-100 15100590-1 2004 OBJECTIVE: To compare the overall analgesic effect, including time to onset, peak and duration of effect for etoricoxib 120 mg, a new COX-2 selective inhibitor, in patients with acute pain to that of placebo. Etoricoxib 109-119 mitochondrially encoded cytochrome c oxidase II Homo sapiens 134-139 15100590-8 2004 DISCUSSION: Etoricoxib is a new COX-2 selective inhibitor under development for treatment of osteoarthritis, rheumatoid arthritis, and acute pain. Etoricoxib 12-22 mitochondrially encoded cytochrome c oxidase II Homo sapiens 32-37 15270001-2 2004 Etoricoxib has a higher COX-1/COX-2 selectivity ratio than the other COX-2-selective NSAIDs as rofecoxib, valdecoxib or celecoxib. Etoricoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 30-35 14965322-1 2004 Novel coxibs (i.e. etoricoxib, valdecoxib, parecoxib and lumiracoxib) with enhanced biochemical cyclooxygenase (COX)-2 selectivity over that of rofecoxib and celecoxib have been recently developed. Etoricoxib 19-29 mitochondrially encoded cytochrome c oxidase II Homo sapiens 96-118 14996519-1 2004 BACKGROUND: Based on the experience with selective cyclooxygenase (COX)-2 inhibitors, including rofecoxib, valdecoxib, and celecoxib, it was anticipated that etoricoxib, a new selective COX-2 inhibitor, would display mechanism-based, dose-dependent renal adverse effects (AEs) similar to those observed with nonselective non-steroidal anti-inflammatory drugs (NSAIDs) in long-term treatment. Etoricoxib 158-168 mitochondrially encoded cytochrome c oxidase II Homo sapiens 51-73 14996519-1 2004 BACKGROUND: Based on the experience with selective cyclooxygenase (COX)-2 inhibitors, including rofecoxib, valdecoxib, and celecoxib, it was anticipated that etoricoxib, a new selective COX-2 inhibitor, would display mechanism-based, dose-dependent renal adverse effects (AEs) similar to those observed with nonselective non-steroidal anti-inflammatory drugs (NSAIDs) in long-term treatment. Etoricoxib 158-168 mitochondrially encoded cytochrome c oxidase II Homo sapiens 186-191 14965322-6 2004 Etoricoxib shows only a slightly improved COX-2 selectivity than rofecoxib, a highly selective COX-2 inhibitor that has been reported to halve the incidence of serious gastrointestinal toxicity compared to nonselective nonsteroidal antiinflammatory drugs (NSAIDs). Etoricoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 42-47 14965322-6 2004 Etoricoxib shows only a slightly improved COX-2 selectivity than rofecoxib, a highly selective COX-2 inhibitor that has been reported to halve the incidence of serious gastrointestinal toxicity compared to nonselective nonsteroidal antiinflammatory drugs (NSAIDs). Etoricoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 95-100 15124935-5 2004 Selective COX-2 inhibitors currently used in the clinic are the sulphonamides celecoxib and valdecoxib (parecoxib is a prodrug of valdecoxib), as well as the methylsulphones rofecoxib and etoricoxib. Etoricoxib 188-198 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 15141994-7 2004 The specificity of etoricoxib for COX-2 has been found to be approximately 3-fold greater than that of rofecoxib and valdecoxib and approximately 14-fold more than celecoxib in human whole blood assays. Etoricoxib 19-29 mitochondrially encoded cytochrome c oxidase II Homo sapiens 34-39 12033987-1 2002 BACKGROUND: Etoricoxib is a highly selective COX-2 inhibitor which was evaluated for the treatment of rheumatoid arthritis (RA). Etoricoxib 12-22 mitochondrially encoded cytochrome c oxidase II Homo sapiens 45-50 12817520-0 2003 Characterization of etoricoxib, a novel, selective COX-2 inhibitor. Etoricoxib 20-30 mitochondrially encoded cytochrome c oxidase II Homo sapiens 51-56 12817520-1 2003 Etoricoxib is a potent selective COX-2 inhibitor in man. Etoricoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 33-38 12817520-12 2003 Based on these results, etoricoxib is a potent selective inhibitor of COX-2 after single and multiple dosing regimens and does not inhibit prostaglandin synthesis in the gastric mucosa, even at doses above the clinical dose range of 60 to 120 mg. Etoricoxib 24-34 mitochondrially encoded cytochrome c oxidase II Homo sapiens 70-75 12800464-2 2003 Etoricoxib, a selective COX2 inhibitor, has been shown to be as effective as non-selective non-steroidal anti-inflammatory drugs in the management of chronic pain in rheumatoid arthritis and osteoarthritis, for periods of up to one year. Etoricoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 24-28 12800464-7 2003 However, etoricoxib shows promise as a new and effective COX2 inhibitor in clinical practice. Etoricoxib 9-19 mitochondrially encoded cytochrome c oxidase II Homo sapiens 57-61 12562317-0 2003 Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. Etoricoxib 25-35 mitochondrially encoded cytochrome c oxidase II Homo sapiens 55-59 12562317-1 2003 The development of COX2 inhibitors with improved biochemical selectivity (such as etoricoxib and valdecoxib) over that of commercially available coxibs has been driven by the potential advantage of safety using higher coxib doses for increased efficacy. Etoricoxib 82-92 mitochondrially encoded cytochrome c oxidase II Homo sapiens 19-23 12562317-4 2003 Etoricoxib has an in vitro COX1/COX2 IC(50) ratio of 344, the highest of any coxib. Etoricoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 32-36 12562317-6 2003 The profound inhibition of monocyte COX2 activity at 24 h after dosing, as predicted by a pharmacological half-life of approximately 22 h, supports a once-daily dosing regimen of etoricoxib. Etoricoxib 179-189 mitochondrially encoded cytochrome c oxidase II Homo sapiens 36-40 12907325-0 2003 The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Etoricoxib 61-71 mitochondrially encoded cytochrome c oxidase II Homo sapiens 35-40 14552704-8 2003 Etoricoxib, showing only a slightly higher COX-2 selectivity than rofecoxib in vitro (COX-1/COX-2 ratio: 344 vs 272, respectively), has been reported to cause a similar specific COX-2 inhibition ex vivo that should translate into comparable GI safety. Etoricoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 43-48 14552704-8 2003 Etoricoxib, showing only a slightly higher COX-2 selectivity than rofecoxib in vitro (COX-1/COX-2 ratio: 344 vs 272, respectively), has been reported to cause a similar specific COX-2 inhibition ex vivo that should translate into comparable GI safety. Etoricoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 92-97 14552704-8 2003 Etoricoxib, showing only a slightly higher COX-2 selectivity than rofecoxib in vitro (COX-1/COX-2 ratio: 344 vs 272, respectively), has been reported to cause a similar specific COX-2 inhibition ex vivo that should translate into comparable GI safety. Etoricoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 92-97 12868201-3 2003 Slow, time-dependent, irreversible, highly selective inhibitors of COX-2 such as celecoxib, etoricoxib, rofecoxib and valdecoxib, so-called coxibs, are a new group of drugs widely used in rheumatology as well as in other fields of medicine. Etoricoxib 92-102 mitochondrially encoded cytochrome c oxidase II Homo sapiens 67-72 12017209-1 2002 OBJECTIVE: To evaluate the efficacy of 12 weeks of treatment with etoricoxib, a selective COX-2 inhibitor, in patients with osteoarthritis (OA) of the knee or hip. Etoricoxib 66-76 mitochondrially encoded cytochrome c oxidase II Homo sapiens 90-95 12564662-3 2002 Valdecoxib, etoricoxib, DFU and DFP inhibited platelet COX-1 and monocyte COX-2 with the following COX-1/COX-2 IC50 ratios: 61.5, 344, 660 and 1918, respectively. Etoricoxib 12-22 mitochondrially encoded cytochrome c oxidase II Homo sapiens 105-110 12564662-3 2002 Valdecoxib, etoricoxib, DFU and DFP inhibited platelet COX-1 and monocyte COX-2 with the following COX-1/COX-2 IC50 ratios: 61.5, 344, 660 and 1918, respectively. Etoricoxib 12-22 mitochondrially encoded cytochrome c oxidase II Homo sapiens 74-79 12466002-1 2002 Etoricoxib is a cyclo-oxygenase (COX)-2-selective NSAID with a higher COX-1 to COX-2 selectivity ratio than the other COX-2-selective NSAIDs rofecoxib, valdecoxib or celecoxib. Etoricoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 79-84 11327589-0 2001 In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663). Etoricoxib 133-143 mitochondrially encoded cytochrome c oxidase II Homo sapiens 117-122 11327589-0 2001 In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663). Etoricoxib 145-152 mitochondrially encoded cytochrome c oxidase II Homo sapiens 117-122 11327589-1 2001 Characterization of the metabolites of the COX-2 inhibitor etoricoxib (MK-0663 and L-791,456) produced in vitro indicate formation of an N-oxide pyridine and hydroxymethyl pyridine that can further be glucuronidated or oxidized to an acid. Etoricoxib 59-69 mitochondrially encoded cytochrome c oxidase II Homo sapiens 43-48 11327589-1 2001 Characterization of the metabolites of the COX-2 inhibitor etoricoxib (MK-0663 and L-791,456) produced in vitro indicate formation of an N-oxide pyridine and hydroxymethyl pyridine that can further be glucuronidated or oxidized to an acid. Etoricoxib 71-78 mitochondrially encoded cytochrome c oxidase II Homo sapiens 43-48